Preprint
Article
Short-Term Evolution after Mitral Transcatheter Edge-to-Edge Repair: Clinical Value of Novel Echocardiographic Biomarkers
Altmetrics
Downloads
106
Views
63
Comments
0
supplementary.docx (16.66KB )
This version is not peer-reviewed
Submitted:
08 May 2024
Posted:
09 May 2024
You are already at the latest version
Alerts
Abstract
Background. Transcatheter edge-to-edge repair (TEER) is a safe and effective treatment in symptomatic patients with mitral regurgitation (MR). We aimed to investigate the short-term impact of mitral TEER on left ventricular (LV) performance and identify echocardiographic prognostic indicators. Methods. Seventy-eight patients with severe MR (organic and functional etiologies) were included retrospectively. All patients had a baseline and short-term echocardi-ography after TEER and were followed up for the primary composite endpoint (heart failure hos-pitalization and cardiovascular death) over a median period of 13 months. Results. A significant decrease in left ventricular ejection fraction (LVEF), all myocardial work indices (except global wasted work), and left atrial reservoir were observed after TEER. Additionally, there was an im-provement in the pulmonary artery systolic pressure and tricuspid annular plane systolic excur-sion/pulmonary artery systolic pressure (TAPSE/PASP) ratio. 34% of all patients presented the primary composite endpoint. A TAPSE/PASP ratio post-TEER < 0.47 (HR: 4.76, p-value = 0.039), and left atrial reservoir post-TEER < 9.0% (HR: 2.77, p-value = 0.047) were independently associ-ated with the primary endpoint. Conclusions. Echocardiography post-TEER reflects impairment in ventricular performance due to preload reduction and right ventricular to pulmonary artery coupling improvement. Short-term echocardiography after TEER identifies high-risk patients who could benefit from a close clinical follow-up.
Keywords:
Subject: Medicine and Pharmacology - Cardiac and Cardiovascular Systems
1. Introduction
Mitral regurgitation (MR) is the second-most frequent valvular heart disease [1] and the underlying mechanism may be primary or secondary [1]. The main causes of primary MR are mitral valve prolapse and chordal rupture (flail leaflet) [2]. Secondary MR is seen in dilated or ischemic cardiomyopathies (ventricular MR) and patients with longstanding atrial fibrillation (atrial MR) [3].
Based on the European guidelines on the management of patients with valvular heart disease, transcatheter edge-to-edge repair (TEER) may be considered in symptomatic patients with severe primary MR at high operative risk (class IIb recommendation) [1]. On the other hand, TEER should be considered in symptomatic patients with severe secondary MR, despite optimal medical therapy, who are not appropriate for surgery (class IIa recommendation) [1,4,5,6].
Longitudinal data on reverse cardiac remodeling and outcomes after TEER are limited [7]. Given that left ventricular ejection fraction (LVEF) might not be an optimal metric for left ventricular (LV) systolic performance in this population, novel echocardiographic biomarkers such as left ventricular global longitudinal strain (LV GLS) and myocardial work (MW) indices have been proposed [8]. Moreover, left atrial (LA) strain and right ventricle to pulmonary arterial (RV-PA) coupling have emerged as relevant prognostic indicators in patients with MR treated with TEER [7].
Importantly, heart failure readmissions and all-cause mortality during the first year after TEER remain substantial, occurring in nearly 17% of cases, even after a successful procedure [9,10].
Therefore, our study aimed to investigate the short-term impact of mitral TEER on LV performance and determine echocardiographic prognostic indicators to identify high-risk patients who could benefit from a close clinical follow-up.
2. Materials and Methods
2.1. Study Population
This was an observational retrospective longitudinal cohort study in patients with moderate-to-severe or severe MR treated with TEER in a tertiary hospital between 2020 and 2023. For this analysis, only patients with complete transthoracic echocardiography (TTE) at baseline (one month before TEER) and short-term follow-up (median: 6 months, interquartile range [IQR]: 3 to 9 months) were included.
A total of 110 patients underwent TEER, 12 of whom did not have a comprehensive baseline TTE (Figure 1). Moreover, 20 patients had insufficient quality imaging or an incomplete TTE six months after TEER (Figure 1). As a result, we finally recruited 78 patients into the study: 49 (62.8%) patients with organic MR and 29 (37,2%) with functional MR (Figure 2).
Demographic and clinical information were collected from the patient’s electronic medical records. Patients were monitored for the primary composite endpoint, defined as heart failure hospitalization and cardiovascular death. The median follow-up period was 13 months after TEER (IQR: 5 to 20 months) (Figure 2).
We assessed the clinical value of novel echocardiographic indices obtained in baseline TTE and post-TEER TTE in identifying patients at high risk for heart failure hospitalization and cardiovascular death. Given the study's small sample size and the limited number of events observed during the relatively short clinical follow-up period, our analysis should be considered as a hypothesis-generating research.
The study was conducted in compliance with the “Good Clinical Practice” guidelines outlined in the Declaration of Helsinki and was approved by the Ethics Committee of the Vall d’Hebron Hospital (PR(AG)119/2024).
2.2. Echocardiography Data
Echocardiography exams were performed by expert imaging cardiologists, and measurements were obtained following European Association of Cardiovascular Imaging (EACVI) standards [3,11,12] and confirmed by a senior expert. All TTE exams were performed with standard equipment (Vivid 95, General Electric Healthcare, Horten, Norway). Two expert and independent cardiologists blinded to patients’ outcomes reviewed all images at the EchoPAC Workstation.
TTE data were obtained at baseline (one month before TEER) and after TEER (median 6 months, IQR: 3 to 9 months), including MR grade, transmitral mean pressure gradient, LV diameters and volumes, LVEF, LV GLS, MW indices, LA volumes, LA strain, tricuspid regurgitation (TR) grade, tricuspid annular plane systolic excursion (TAPSE), right ventricular strain free wall (RV FWS), pulmonary artery systolic pressure (PASP), and TAPSE/PASP ratio.
According to EACVI recommendations, MR was classified as grade 1, 2, 3, or 4 [3]. Procedural success was defined as reducing the severity of the MR to grade 2 or less in TTE after TEER [5]. TEER complications were classified as either procedure-related or device-related [13].
LV diameters were measured on the parasternal axis and LV volumes were measured in apical four- and two-chamber views. LVEF was calculated using Simpson’s biplane method, while LA volume was calculated using the biplane method. Speckle tracking echocardiography was used to assess LV and LA strains. LV GLS was obtained using apical four-chamber, two-chamber, and apical long-axis views [11]. The atrial strain was calculated in the reservoir phase using a four- and two-chamber view [12].
The assessment of LV MW incorporates blood pressure measurements to estimate the LV afterload [4]. MW is measured from pressure-strain loop areas that are constructed from the LV pressure curves combined with LV GLS [14]. Peak systolic LV pressure is assumed to be equal to the peak arterial pressure recorded from brachial cuff systolic pressure before the echocardiographic study in a supine position.
MW comprises multiple components: global work index (GWI), global constructed work (GCW), global wasted work (GWW), and global work efficiency (GWE) [15,16]. The NORRE study provides useful reference ranges for novel indices of noninvasive MW in healthy volunteers over a wide range of ages and genders [17]. We can see an example of MW evaluation in Figure 3.
According to EACVI recommendations, TR was classified as grade 1, 2, 3, or 4 [3]. Right ventricular function was calculated using TAPSE and RV FWS. The right atrial-right ventricular systolic gradient was determined from the peak velocity of the TR jet using the simplified Bernoulli equation [9]. Right atrial pressure was estimated by the diameter and collapsibility of the inferior vena cava and added to the calculated gradient to yield PASP [9]. TAPSE/PASP was then obtained [9], being a noninvasive index to assess RV-PA coupling [18].
2.3. Statistical Analysis
The distribution of variables was analyzed through graphical evaluation (histogram and Q–Q graph) and the Shapiro–Wilk test. Continuous variables were expressed as means and standard deviations when the normality assumption was met, whereas those not following a normal distribution were presented as medians and IQR ranges. Continuous variables were compared using the Student’s t-test or Mann-Whitney U-test, as appropriate. Categorical variables were expressed as absolute numbers and percentages and were compared using the chi-square test or Fisher’s exact test, as appropriate.
To analyze the differences between six months post-TEER and baseline pre-TEER imaging markers, we applied a paired T-test, a Wilcoxon test, or a McNemar test, as appropriate.
Cox regression analysis assessed the association between clinical and echocardiographic parameters with the composite endpoint of “heart failure hospitalization and cardiovascular death.” Youden’s index was performed to determine the cut-off values for echocardiography markers that best predict the composite endpoint. Survival curves for “TAPSE/PASP post-TEER” and “LA reservoir strain post-TEER” were constructed using the Kaplan–Meier method; survival was assessed starting from the time of post-TEER echocardiographic reassessment. “Mitral regurgitation etiology”, “TAPSE/PASP ratio post-TEER”, and “LA reservoir post-TEER” were introduced into Cox multivariate regression analysis.
A p-value < 0.05 indicated statistical significance. Statistical analysis was performed using R Core Team (version 4.3.2 for Mac OSX).
3. Results
3.1. Baseline Characteristics of the Cohort
The mean age was 74 ± 9 years and 46% were females. Most patients were symptomatic; 65.4% were New York Heart Association (NYHA) class III to IV. All patients were on optimal medical treatment before TEER (Table 1).
The median effective regurgitant orifice area (EROA) was 37.0 mm2, IQR: 30.0-40.0 mm2. Primary or organic MR was the main etiology (49 patients, 62.8%), while functional or secondary etiology was less frequent (29 patients, 37.2%). Within the functional MR subgroup, we included patients with atrial MR (11 patients, 37.9%) and ventricular MR (18 patients, 62.1%). Clinical and echocardiographic baseline characteristics are shown in Table 1 and Table 2.
49 patients (62.8%) had known atrial fibrillation and 54 (69.2%) had prior heart failure hospitalization. No differences were observed in the heart failure hospitalization rate between patients with organic and functional MR (71.4% versus 65.5%, p-value = 0.826). 33 patients (42.3%) had chronic kidney disease and 12 (15.3%) had chronic obstructive pulmonary disease.
Before the percutaneous procedure, 20 patients (25.6%) had an MR grade of III, while 58 patients (74.4%) had grade IV MR. Patients with organic MR exhibited more severe MR than patients with functional MR (mean EROA 40 mm2 versus 30 mm2, p-value = 0.038).
The median LVEF was 50.0% (IQR: 36-60%). In patients with organic MR, LV volumes were larger than those with functional MR, particularly LV end-diastolic volume (LVEDV) and indexed LV end-diastolic volume (LVEDVI); Table 2. No differences were detected in MW indices (GWI, GCW, GWW, GWE) at baseline between patients with organic and functional MR (Table 2). LV GLS (-13.76 ± 3.88%) and LA strain (mean 10%, IQR: 7.00-16.0%) were reduced at baseline.
In the functional MR cohort, patients with atrial MR had higher LVEF and lower volumes than patients with ventricular MR: mean LVEF 58.0% (IQR: 55.0-62.0%) versus 40.5% (IQR: 34.2-54.0%), p-value = 0.003; mean LVEDVI 89 ml (IQR: 79-110 ml) versus 115 ml (IQR: 100-184 ml), p-value = 0.038.
There were no significant differences in baseline TAPSE, PASP, or TAPSE/PASP ratio values between patients with organic or functional MR (Table 2). Of the patients treated with mitral TEER, 65.3% did not present significant TR (≤ 2) before the procedure.
Principio del formulario
3.2. Safety and Effectiveness of Mitral TEER in Our population.
Different devices were used for the TEER procedure, primarily MitraClip in 96% of cases and Pascal in 4%. Thirty percent of the cohort required more than one device to effectively treat MR.
A significant reduction in MR grade was observed in the overall population after TEER (p-value < 0.001). TEER was successful in 51 patients (65.4%), without significant differences between patients with organic and functional MR regarding the procedure’s rate success (65.3% versus 65.5% p-value = 0.691). Following TEER, the transmitral mean gradient consistently increased (2.21 ± 0.83 mmHg before TEER versus 3.95 ± 1.94 after TEER, p-value < 0.001).
In the present study, eight complications were reported (10.2%). Three of these complications (3.8%) were procedure-related, with two cases of tamponade and one vascular access site complication. Five (6.4%) were device-related: two patients had a chordal rupture and required urgent surgery, two other patients experienced partial clip detachment and needed a second percutaneous procedure, and there was one case of leaflet perforation treated conservatively due to high surgical risk.
3.3. Short-Term Impact of TEER on Left Ventricular Remodeling
Table 3 and Figure 4 show changes in LV, LA, and right ventricular performance six months after TEER (IQR: 3 to 9 months). A significant reduction in LVEF was observed (delta –3.63 ± 8.18, p-value < 0.001). Decreased LVEF after correction of MR occurs because of a greater decline in LV end-diastolic diameter (LVEDD) and LVEDV compared with LV end-systolic diameter (LVESD) and LV end-systolic volume (LVESV), Table 3.
Moreover, an impairment in all myocardial indices (GWI, GCW, GWE) was observed following the acute reduction in LV preload, except for GWW (Table 3). LV GLS also tended to decrease after TEER, although it did not reach statistical significance (-13.28 ± 3.82 versus -12.28 ± 3.97; p-value = 0.085). LA reservoir strain also diminished after TEER (12.03 ± 6.38 versus 10.00 ± 4.56; p-value = 0.002).
No changes in right ventricular function (TAPSE, RV FWS) were reported after TEER (Table 3). A significant and early improvement in PASP values after the percutaneous procedure was observed (53.64 ± 18.64 mmHg before TEER versus 43.86 ± 14.92 mmHg after TEER; p-value < 0.001).
Furthermore, an improvement in TAPSE/PASP was observed (0.39 ± 0.19 before TEER versus 0.45 ± 0.18 after TEER; p-value = 0.021), translating as beneficial changes in RV-PA coupling.
3.4. Impact of TEER at Follow-Up: Heart Failure Hospitalizations and Cardiovascular Death after TEER.
The primary composite endpoint occurred in 27 patients (34.6%). There were no differences in the primary endpoint between patients with organic or functional MR: twenty events (40.8%) versus seven events (24.1%), p-value = 0.211 (Figure 5).
The association between clinical and echocardiographic variables with the primary endpoint (univariable analysis) is shown inTable 4. A higher risk of HF hospitalization or cardiovascular death was present among patients with diabetes (HR: 2.25, 95% CI: 1.02-4.98, p-value = 0.045) and those with prior heart failure hospitalization (HR: 3.69, 95% CI: 1.26-10.83, p-value = 0.017). In addition, a lower reservoir value of LA strain post-TEER (p-value = 0.024) and a lower TAPSE/PASP ratio post-TEER (p-value = 0.038) were also associated with the primary endpoint, which was not verified when TAPSE and PASP were analyzed separately (Table 4).
In the Kaplan–Meier survival analysis (Figure 6), patients with TAPSE/PASP post-TEER < 0.47 had a higher risk of reaching the primary composite endpoint (HR: 4.76, 95% CI: 1.08-21.02, p-value = 0.039). Moreover, patients with an LA reservoir post-TEER < 9.0% also had an increased risk of reaching the primary composite endpoint (HR: 2.77, 95% CI: 1.01-7.59, p-value = 0.047).
When MR etiology was introduced into the Cox multivariate regression analysis, TAPSE/PASP post-TEER < 0.47 remained an independent prognostic indicator of the primary composite endpoint (HR: 4.67, 95% CI: 1.04-20.93, p-value = 0.043), together with LA reservoir post-TEER < 9.0% (HR: 3.08, 95% CI: 1.08-8.76, p-value = 0.034).
4. Discussion
TEER is a safe and effective treatment in symptomatic patients with MR. However, data on reverse cardiac remodeling and outcomes after TEER are limited. We evaluated the short-term impact of mitral TEER on cardiac performance using novel echocardiographic biomarkers such as LV strain, MW, TAPSE/PASP ratio, or LA strain. An impairment in ventricular performance due to preload reduction and RV-PA coupling improvement was observed at short-term follow-up after TEER. Additionally, we evaluated the clinical value of these novel echocardiographic indices for risk stratification and treatment guidance. The TAPSE/PASP ratio and LA reservoir appeared to be relevant independent prognostic indicators in patients with MR who were treated with TEER.
Contrasting with previously published studies, the present study mainly included patients with organic MR (62.8%), with functional MR being less frequent (37.2%). The EVEREST trial included patients with organic and functional MR [20]. However, organic MR only represented 41% of the patients [20]. The COAPT trial only included patients with functional MR, and patients with predominant atrial MR without LV dysfunction were excluded [21]. So far, there is little evidence in the literature regarding clinical outcomes of TEER in series with a predominance of organic MR patients.
In the present cohort, patients with organic MR exhibited higher ventricular volumes (LVEDV, LVEDVI) than those with functional MR. Moreover, slightly lower LV volumes were observed compared with EVEREST trial patients, and significantly lower LV volumes and higher LVEF compared with COAPT trial patients (Table S1 in Supplementary Materials).
Distinct reasons can explain these differences. Firstly, the present functional MR cohort had a significant prevalence of patients without cardiomyopathy (37.9%) due to an atrial mechanism of the MR. Importantly, these patients are characterized by preserved LV function and LV volumes, in contrast to patients with ventricular MR [22]. Furthermore, ventricular functional MR was only treated in patients with “disproportionate” MR, characterized by severe MR, an acceptable LVEF, and non-markedly dilatated ventricles.
Our series showed that patients with functional MR exhibited a non-significantly higher LA volume, lower LA strain reservoir and a higher prevalence of atrial fibrillation, partially attributed to an atrial mechanism.
TEER was successful in 51 patients (65.4%) with a residual MR grade 1 or 2 at short-term follow-up. Notably, no significant differences regarding the procedure's success were observed between patients with organic and functional MR. These results are similar to the Spanish real-life registry, which showed a maintained MR reduction (grade 1 or 2) in 73% of patients 12 months after TEER [10].
The primary composite endpoint (heart failure hospitalization and cardiovascular death) occurred in 27 patients (34.6%). As in the previously commented registry [10], there was no difference in the primary endpoint between patients with organic or functional MR.
LVEF, myocardial work indices, and LV remodeling.
As expected, a significant decrease in LVEF was observed after TEER. After MR correction, patients with preserved baseline LVEF may experience a decrease in LVEF due to a greater reduction in LVEDV compared with LVESV [23, 24].
Regarding myocardial indexes, different studies evaluated changes after TEER [5,14,25,26]. All myocardial indices (GWI, GCW, GWE) were impaired in the short-term evolution in the present series, except for GWW, due to preload reduction. Similar results were published by Galli et al. in patients with organic MR [25]. Yedidya et al. noted that the forward stroke volume index was the only echocardiographic parameter that improved six months after TEER in patients with functional MR [26].
At extended follow-up, Galli et al. reported that GLS, GWI, and GWE recovered one year after TEER, however, not GWW [25]. The fact that GWW remained impaired might be attributable to the persistence of myocardial fibrosis [27,28]. GWW could be higher in patients with advanced disease, and it could delay reverse LV remodeling, negatively impacting the LV response to MR correction [25] with worse long-term survival [4]. Papadopoulos et al. also reported long-term beneficial changes in ventricular remodeling after TEER, with a reduction in LV volumes and significant improvement of GWI and GCW in patients with functional MR [14]. GWI and GCW were also independently associated with worse long-term survival [4].
RV-PA coupling: changes after TEER and clinical outcomes.
In our series, we reported a significant and early improvement in PASP values and the TAPSE/PASP ratio after TEER, similar to Adamo M. et al., who reported that 66% of patients enhanced their TAPSE/PASP ratio at short-term follow-up after TEER [18]. This fact has important clinical significance because lower pulmonary pressure is one of the main determinants of reverse LV remodeling, as described by Cimino et al. [6]. Additionally, an improvement in TAPSE/PASP after TEER was independently associated with a reduced risk of mortality at long-term follow-up [18].
In our series, patients with TAPSE/PASP post-TEER < 0.47 had a higher risk of reaching the primary composite endpoint. An impaired TAPSE/PASP ratio after TEER could be attributed to an increase in PASP, which may be partially explained by the persistence of significant residual MR after TEER due to a non-optimal procedure [18], higher postprocedural mitral mean gradients [18], or associated LV systolic or diastolic dysfunction. In addition, a reduced TAPSE/PASP ratio after TEER could be explained by a decrease in TAPSE in patients who are treated in an advanced stage of the disease accompanied by right ventricle systolic dysfunction.
LA strain in patients treated with TEER and clinical outcomes.
Increasing preload can enhance reservoir function in the initial stages of MR when the LA is not rigid [23]. However, LA strain decreases with increasing MR grade [23,29]. In the present cohort, a reduced baseline LA strain was observed, suggesting patients had advanced disease. In cases of LA stiffness, the left atrium cannot compensate for the change in preload, leading to hemodynamic failure, such as pulmonary edema [23,30].
Previous studies reported that the TAPSE/PASP ratio presented a significant negative correlation with the baseline LA v-wave [9]. Moreover, an improvement in RV-PA coupling was linked to an incremental LA reservoir [9]. However, RV-PA coupling progress was not associated with beneficial changes in LA function in our study. In fact, the LA reservoir decreased significantly after TEER and was accompanied by a reduction in LV GLS, suggesting that the LA reservoir mainly depends on LV longitudinal function [23]. In addition, LA strain impairment after TEER may result from a residual MR grade 2 or higher, which makes the LA reservoir decline further, as observed by Gucuk Ipek et al. [23].
In our series, patients with an LA reservoir post-TEER < 9.0% had a higher risk of reaching the primary composite endpoint. A deteriorated LA strain may indicate advanced and irreversible LA dysfunction, negatively affecting the prognosis [9,23,30].
Risk stratification with echocardiographic markers.
Due to their prognostic implications, patients with a deteriorated TAPSE/PASP ratio or LA reservoir in short-term TTE after TEER could benefit from close clinical follow-up. In this context, short-term echocardiography performed by imaging experts after TEER is essential to improve risk stratification and identify high-risk patients who could benefit from stricter monitoring and more aggressive medical treatment during clinical follow-up.
On the other hand, early intervention for MR seems crucial to prevent adverse LV remodeling. It would be interesting to identify TTE patients at baseline who could benefit from an anticipated TEER and avoid futility in patients already in advanced-stage disease. However, our study was not able to determine echocardiographic prognostic predictors in the baseline TTE, probably due to a low statistical power. In contrast, Trejo-Velasco et al. found that patients with MR treated with TEER had higher rates of heart failure readmissions and all-cause mortality if the baseline TAPSE/PASP ratio was ≤ 0.35 [9]. Additionally, Stassen et al. published that a more preserved baseline LA reservoir (≥ 9.8%) in patients with functional MR was independently associated with lower all-cause mortality [29].
Study limitations.
This retrospective, single-center, real-life study comprises a limited and heterogeneous population with MR caused by different etiologies and a relatively short follow-up period. In future studies, we should focus on single etiology MR as patients with organic MR, ventricular functional MR, and atrial functional MR exhibited a differentiated physiopathology and likely a distinct clinical evolution. The retrospective study design may include a selection bias because some patients were excluded due to the insufficient quality of their echocardiography imaging.
Ventricular volumes were calculated by Simpson’s biplane method and not by 3D echocardiography. MW combines longitudinal myocardial deformation and afterload measures [31]. Despite this advantage, pressure-strain analysis does not differentiate between forward and regurgitant volume, which remains a limitation for assessing LV function in MR [31]. For this reason, the forward stroke volume index should be considered in future studies [26]. Moreover, there is only one vendor platform with a noninvasive MW algorithm (GE Healthcare) [15,16]. This fact and the great variety of MW parameters might represent a limitation for the broad application of MW in clinical practice [15,16].
Because of the study's small sample size and the limited number of events observed during the short clinical follow-up period, our analysis serves as a hypothesis-generating research. Consequently, the prognostic significance of LA strain and the TAPSE/PASP ratio should be validated in subsequent large-scale prospective studies.
5. Conclusions
Echocardiography post-TEER reflects impairment in ventricular performance (LVEF, LV GLS and most MW indices) due to preload reduction. However, there was an improvement in PASP and the TAPSE/PASP ratio, translating into beneficial changes in RV-PA coupling.
The TAPSE/PASP ratio and LA reservoir obtained in short-term TTE after TEER were revealed as relevant prognostic indicators associated with a higher rate of adverse events (heart failure hospitalization and cardiovascular death). Therefore, echocardiography post-TEER is crucial to identify high-risk patients who could benefit from close clinical follow-up.
Supplementary Materials
The following supporting information can be downloaded at the website of this paper posted on Preprints.org; Table S1: Baseline characteristics of our cohort, EVEREST, and COAPT patients.
Author Contributions
F.G.-R., G.F.-V., and M.-G. conceptualized the dataset. S.C.-J. and F.G.-R. wrote the original draft of the main manuscript. A.-L. performed the statistical analysis. R.-J. and S.-L. helped in data curation and data analysis. G.G.-L., S.C.-J., F.-I., and R.P.-J.F. reviewed and edited the main manuscript for the last version. A.-L., B.-Y., and S.C.J. analyzed the results and prepared the figures. G.F.-V., F.G.-R., V.-N., T.-G., C.-G., V.-F., and O.-R. performed the echocardiography and recruited the participants. R.P.-J.F., F.-I., G.-B., and G.G.-L. supervised the process. All authors have read and agreed to the published version of the manuscript.
Funding
This research received no external funding.
Institutional Review Board Statement
This study was conducted according to the principles of the Declaration of Helsinki and was approved by the Institutional Review Board and Ethics Committee of the Hospital Universitari Vall d’Hebron.
Informed Consent Statement
Informed consent was obtained from all subjects involved in this study.
Data Availability Statement
The data presented in this study are available upon request from the corresponding author. The data are not publicly available due to ethical reasons.
Acknowledgments
Belahnech, Y. is supported by a research non-conditioned grant (Rio Hortega CM22/00242).
Conflicts of Interest
The authors declare no conflicts of interest.
Abbreviations
| EROA | effective regurgitant orifice area |
| GCW | global constructive work |
| GLS | global longitudinal strain |
| GWE | global work efficiency |
| GWI | global work index |
| LA | left atrial |
| LV | left ventricle |
| LVEDD | left ventricular end-diastolic diameter |
| LVEDV | left ventricular end-diastolic volume |
| LVEDVI | indexed left ventricular end-diastolic volume |
| LVEF | left ventricle ejection fraction |
| LVESD | left ventricular end-systolic diameter |
| LVESV | left ventricular end-systolic volume |
| MR | mitral regurgitation |
| MW | myocardial work |
| PASP | pulmonary artery systolic pressure |
| RV FWS | right ventricular free wall longitudinal strain |
| RV | right ventricle |
| RV-AP | right ventricle to pulmonary arterial |
| TAPSE | tricuspid annular plane systolic excursion |
| TEER | transcatheter edge-to-edge repair |
| TR | tricuspid regurgitation |
| TTE | transthoracic echocardiography |
References
- Vahanian, A.; Beyersdorf, F.; Praz, F.; Milojevic, M.; Baldus, S.; Bauersachs, J.; Capodanno, D.; Conradi, L.; De Bonis, M.; De Paulis, R.; Delgado, V.; Freemantle, N.; Gilard, M.; Haugaa, K. H.; Jeppsson, A.; Jüni, P.; Pierard, L.; Prendergast, B. D.; Sádaba, J. R.; Tribouilloy, C.; Wojakowski, W.; ESC/EACTS Scientific Document Group; Neumann, F.-J.; Myers, P.; Abdelhamid, M.; Achenbach, S.; Asteggiano, R.; Barili, F.; Borger, M. A.; Carrel, T.; Collet, J.-P.; Foldager, D.; Habib, G.; Hassager, C.; Irs, A.; Iung, B.; Jahangiri, M.; Katus, H. A.; Koskinas, K. C.; Massberg, S.; Mueller, C. E.; Nielsen, J. C.; Pibarot, P.; Rakisheva, A.; Roffi, M.; Rubboli, A.; Shlyakhto, E.; Siepe, M.; Sitges, M.; Sondergaard, L.; Sousa-Uva, M.; Tarantini, G.; Zamorano, J. L.; Praz, F.; Milojevic, M.; Baldus, S.; Bauersachs, J.; Capodanno, D.; Conradi, L.; De Bonis, M.; De Paulis, R.; Delgado, V.; Freemantle, N.; Gilard, M.; Haugaa, K. H.; Jeppsson, A.; Jüni, P.; Pierard, L.; Prendergast, B. D.; Sádaba, J. R.; Tribouilloy, C.; Wojakowski, W.; ESC National Cardiac Societies; Benchabi, Y.; Chilingaryan, A.; Metzler, B.; Rustamova, Y.; Shumavets, V.; Lancellotti, P.; Smajic, E.; Trendafilova-Lazarova, D.; Samardzic, J.; Karakyriou, M.; Palecek, T.; Sanchez Dahl, J.; Meshaal, M. S.; Palm, K.; Virtanen, M.; Bouleti, C.; Bakhutashvili, Z.; Achenbach, S.; Boutsikou, M.; Kertész, A. B.; Danielsen, R.; Topilsky, Y.; Golino, P.; Tuleutayev, R.; Elezi, S.; Kerimkulov, A.; Rudzitis, A.; Glaveckaite, S.; Sow, R.; Demarco, D. C.; Bulatovic, N.; Aouad, A.; Van Den Brink, R.; Antova, E.; Beitnes, J. O.; Ochala, A.; Ribeiras, R.; Vinereanu, D.; Irtyuga, O.; Ivanovic, B.; Simkova, I.; González Gómez, A.; Sarno, G.; Pedrazzini, G. B.; Bsata, W.; Zakhama, L.; Korkmaz, L.; Cherniuk, S.; Khanji, M. Y.; Sharipov, I. 2021 ESC/EACTS Guidelines for the Management of Valvular Heart Disease. European Heart Journal 2022, 43 (7), 561–632. [CrossRef]
- Pastore, M. C.; Vannuccini, F.; Mandoli, G. E.; Lisi, M.; Iuliano, M. A.; Santoro, A.; Niglio, F. P.; Diviggiano, E. E.; Lorenz, V.; Montesi, G.; Cavigli, L.; Focardi, M.; D’Ascenzi, F.; Cameli, M. Myocardial Work and Left Heart Deformation Parameters across Primary Mitral Regurgitation Severity. International Journal of Cardiology 2024, 399, 131772. [CrossRef]
- Lancellotti, P.; Pibarot, P.; Chambers, J.; La Canna, G.; Pepi, M.; Dulgheru, R.; Dweck, M.; Delgado, V.; Garbi, M.; Vannan, M. A.; Montaigne, D.; Badano, L.; Maurovich-Horvat, P.; Pontone, G.; Vahanian, A.; Donal, E.; Cosyns, B.; the Scientific Document Committee of the European Association of Cardiovascular Imaging. Multi-Modality Imaging Assessment of Native Valvular Regurgitation: An EACVI and ESC Council of Valvular Heart Disease Position Paper. European Heart Journal - Cardiovascular Imaging 2022, 23 (5), e171–e232. [CrossRef]
- Yedidya, I.; Lustosa, R. P.; Fortuni, F.; Van Der Bijl, P.; Namazi, F.; Vo, N. M.; Meucci, M. C.; Ajmone Marsan, N.; Bax, J. J.; Delgado, V. Prognostic Implications of Left Ventricular Myocardial Work Indices in Patients With Secondary Mitral Regurgitation. Circ: Cardiovascular Imaging 2021, 14 (9). [CrossRef]
- Hubert, A.; Galli, E.; Leurent, G.; Corbineau, H.; Auriane, B.; Guillaume, L.; Leclercq, C.; Donal, E. Left Ventricular Function after Correction of Mitral Regurgitation: Impact of the Clipping Approach. Echocardiography 2019, 36 (11), 2010–2018. [CrossRef]
- Cimino, S.; Maestrini, V.; Cantisani, D.; Petronilli, V.; Filomena, D.; Mancone, M.; Sardella, G.; Fedele, F.; Lancellotti, P.; Agati, L. 2D/3D Echocardiographic Determinants of Left Ventricular Reverse Remodelling after MitraClip Implantation. European Heart Journal - Cardiovascular Imaging 2019, 20 (5), 558–564. [CrossRef]
- Koschutnik, M.; Donà, C.; Nitsche, C.; Kammerlander, A. A.; Dannenberg, V.; Brunner, C.; Koschatko, S.; Mascherbauer, K.; Heitzinger, G.; Halavina, K.; Spinka, G.; Winter, M.-P.; Hülsmann, M.; Bartko, P. E.; Hengstenberg, C.; Mascherbauer, J.; Goliasch, G. Impact of Right Ventricular-to-Pulmonary Artery Coupling on Remodeling and Outcome in Patients Undergoing Transcatheter Edge-to-Edge Mitral Valve Repair. Clin Res Cardiol 2023. [CrossRef]
- Verbeke, J.; Calle, S.; Kamoen, V.; De Buyzere, M.; Timmermans, F. Prognostic Value of Myocardial Work and Global Longitudinal Strain in Patients with Heart Failure and Functional Mitral Regurgitation. Int J Cardiovasc Imaging 2022, 38 (4), 803–812. [CrossRef]
- Trejo-Velasco, B.; Estevez-Loureiro, R.; Carrasco-Chinchilla, F.; Fernández-Vázquez, F.; Arzamendi, D.; Pan, M.; Pascual, I.; Nombela-Franco, L.; Amat-Santos, I. J.; Freixa, X.; Hernández-Antolín, R. A.; Trillo-Nouche, R.; Andraka Ikazuriaga, L.; López-Mínguez, J. R.; Sanmiguel Cervera, D.; Sanchis, J.; Diez-Gil, J. L.; Ruiz-Quevedo, V.; Urbano-Carrillo, C.; Becerra-Muñoz, V. M.; Benito-González, T.; Li, C. H.; Mesa, D.; Avanzas, P.; Armijo, G.; Serrador-Frutos, A. M.; Sanchis, L.; Lobán, C. F.-G.; Cid-Álvarez, B.; Hernández-García, J. M.; Garrote-Coloma, C.; Fernández-Peregrina, E.; Romero, M.; León Arguero, V.; Cruz-González, I. Prognostic Role of TAPSE to PASP Ratio in Patients Undergoing MitraClip Procedure. JCM 2021, 10 (5), 1006. [CrossRef]
- Pascual, I.; Arzamendi, D.; Carrasco-Chinchilla, F.; Fernández-Vázquez, F.; Freixa, X.; Nombela-Franco, L.; Avanzas, P.; Serrador Frutos, A. M.; Pan, M.; Cid Álvarez, A. B.; Hernández-Antolín, R. A.; Andraka Ikazuriaga, L.; Cruz-González, I.; Díez Gil, J. L.; Alcasena Juango, M. S.; Berenguer Jofresa, A.; Alonso-Briales, J. H.; Li, C. H.; Benito González, T.; Regueiro, A.; Armijo, G.; León, V.; Amat-Santos, I. J.; Romero, M.; Trillo Nouche, R.; Fernández-Golfín, C.; Ruiz Gómez, L.; Campos-Arjona, R.; Millán, X.; Garrote Coloma, C.; Sanchis, L.; Jiménez-Quevedo, P.; Morís, C.; Hernández-García, J. M.; Serra, A.; Pérez De Prado, A.; Estévez-Loureiro, R. Transcatheter Mitral Repair According to the Cause of Mitral Regurgitation: Real-Life Data from the Spanish MitraClip Registry. Revista Española de Cardiología (English Edition) 2020, 73 (8), 643–651. [CrossRef]
- Voigt, J.-U.; Pedrizzetti, G.; Lysyansky, P.; Marwick, T. H.; Houle, H.; Baumann, R.; Pedri, S.; Ito, Y.; Abe, Y.; Metz, S.; Song, J. H.; Hamilton, J.; Sengupta, P. P.; Kolias, T. J.; d’Hooge, J.; Aurigemma, G. P.; Thomas, J. D.; Badano, L. P. Definitions for a Common Standard for 2D Speckle Tracking Echocardiography: Consensus Document of the EACVI/ASE/Industry Task Force to Standardize Deformation Imaging. European Heart Journal - Cardiovascular Imaging 2015, 16 (1), 1–11. [CrossRef]
- Badano, L. P.; Kolias, T. J.; Muraru, D.; Abraham, T. P.; Aurigemma, G.; Edvardsen, T.; D’Hooge, J.; Donal, E.; Fraser, A. G.; Marwick, T.; Mertens, L.; Popescu, B. A.; Sengupta, P. P.; Lancellotti, P.; Thomas, J. D.; Voigt, J.-U.; Industry representatives; Prater, D.; Chono, T.; Mumm, B.; Houle, H.; Healthineers, S.; Hansen, G.; Abe, Y.; Pedri, S.; Reviewers: This document was reviewed by members of the 2016–2018 EACVI Scientific Documents Committee; Delgado, V.; Gimelli, A.; Cosyns, B.; Gerber, B.; Flachskampf, F.; Haugaa, K.; Galderisi, M.; Cardim, N.; Kaufmann, P.; Masci, P. G.; Marsan, N. A.; Rosca, M.; Cameli, M.; Sade, L. E. Standardization of Left Atrial, Right Ventricular, and Right Atrial Deformation Imaging Using Two-Dimensional Speckle Tracking Echocardiography: A Consensus Document of the EACVI/ASE/Industry Task Force to Standardize Deformation Imaging. European Heart Journal - Cardiovascular Imaging 2018, 19 (6), 591–600. [CrossRef]
- Schnitzler, K.; Hell, M.; Geyer, M.; Kreidel, F.; Münzel, T.; Von Bardeleben, R. S. Complications Following MitraClip Implantation. Curr Cardiol Rep 2021, 23 (9), 131. [CrossRef]
- Papadopoulos, K.; Ikonomidis, I.; Chrissoheris, M.; Chalapas, A.; Kourkoveli, P.; Parissis, J.; Spargias, K. MitraClip and Left Ventricular Reverse Remodelling: A Strain Imaging Study. ESC Heart Failure 2020, 7 (4), 1409–1418. [CrossRef]
- Ilardi, F.; D’Andrea, A.; D’Ascenzi, F.; Bandera, F.; Benfari, G.; Esposito, R.; Malagoli, A.; Mandoli, G. E.; Santoro, C.; Russo, V.; Crisci, M.; Esposito, G.; Cameli, M.; on behalf of the Working Group of Echocardiography of the Italian Society of Cardiology (SIC). Myocardial Work by Echocardiography: Principles and Applications in Clinical Practice. JCM 2021, 10 (19), 4521. [CrossRef]
- Marzlin, N.; Hays, A. G.; Peters, M.; Kaminski, A.; Roemer, S.; O’Leary, P.; Kroboth, S.; Harland, D. R.; Khandheria, B. K.; Tajik, A. J.; Jain, R. Myocardial Work in Echocardiography. Circ: Cardiovascular Imaging 2023, 16 (2). [CrossRef]
- Manganaro, R.; Marchetta, S.; Dulgheru, R.; Ilardi, F.; Sugimoto, T.; Robinet, S.; Cimino, S.; Go, Y. Y.; Bernard, A.; Kacharava, G.; Athanassopoulos, G. D.; Barone, D.; Baroni, M.; Cardim, N.; Hagendorff, A.; Hristova, K.; López-Fernández, T.; De La Morena, G.; Popescu, B. A.; Penicka, M.; Ozyigit, T.; Rodrigo Carbonero, J. D.; Van De Veire, N.; Von Bardeleben, R. S.; Vinereanu, D.; Zamorano, J. L.; Rosca, M.; Calin, A.; Moonen, M.; Magne, J.; Cosyns, B.; Galli, E.; Donal, E.; Carerj, S.; Zito, C.; Santoro, C.; Galderisi, M.; Badano, L. P.; Lang, R. M.; Oury, C.; Lancellotti, P. Echocardiographic Reference Ranges for Normal Non-Invasive Myocardial Work Indices: Results from the EACVI NORRE Study. European Heart Journal - Cardiovascular Imaging 2019, 20 (5), 582–590. [CrossRef]
- Adamo, M.; Inciardi, R. M.; Tomasoni, D.; Dallapellegrina, L.; Estévez-Loureiro, R.; Stolfo, D.; Lupi, L.; Pancaldi, E.; Popolo Rubbio, A.; Giannini, C.; Benito-González, T.; Fernández-Vázquez, F.; Caneiro-Queija, B.; Godino, C.; Munafò, A.; Pascual, I.; Avanzas, P.; Frea, S.; Boretto, P.; Moñivas Palomero, V.; Del Trigo, M.; Biagini, E.; Berardini, A.; Nombela-Franco, L.; Jimenez-Quevedo, P.; Lipsic, E.; Saia, F.; Petronio, A. S.; Bedogni, F.; Sinagra, G.; Guazzi, M.; Voors, A.; Metra, M. Changes in Right Ventricular–to–Pulmonary Artery Coupling After Transcatheter Edge-to-Edge Repair in Secondary Mitral Regurgitation. JACC: Cardiovascular Imaging 2022, 15 (12), 2038–2047. [CrossRef]
- Humbert, M.; Kovacs, G.; Hoeper, M. M.; Badagliacca, R.; Berger, R. M. F.; Brida, M.; Carlsen, J.; Coats, A. J. S.; Escribano-Subias, P.; Ferrari, P.; Ferreira, D. S.; Ghofrani, H. A.; Giannakoulas, G.; Kiely, D. G.; Mayer, E.; Meszaros, G.; Nagavci, B.; Olsson, K. M.; Pepke-Zaba, J.; Quint, J. K.; Rådegran, G.; Simonneau, G.; Sitbon, O.; Tonia, T.; Toshner, M.; Vachiery, J. L.; Vonk Noordegraaf, A.; Delcroix, M.; Rosenkranz, S.; ESC/ERS Scientific Document Group; Schwerzmann, M.; Dinh-Xuan, A. T.; Bush, A.; Abdelhamid, M.; Aboyans, V.; Arbustini, E.; Asteggiano, R.; Barberà, J. A.; Beghetti, M.; Čelutkienė, J.; Cikes, M.; Condliffe, R.; De Man, F.; Falk, V.; Fauchier, L.; Gaine, S.; Galié, N.; Gin-Sing, W.; Granton, J.; Grünig, E.; Hassoun, P. M.; Hellemons, M.; Jaarsma, T.; Kjellström, B.; Klok, F. A.; Konradi, A.; Koskinas, K. C.; Kotecha, D.; Lang, I.; Lewis, B. S.; Linhart, A.; Lip, G. Y. H.; Løchen, M. L.; Mathioudakis, A. G.; Mindham, R.; Moledina, S.; Naeije, R.; Nielsen, J. C.; Olschewski, H.; Opitz, I.; Petersen, S. E.; Prescott, E.; Rakisheva, A.; Reis, A.; Ristić, A. D.; Roche, N.; Rodrigues, R.; Selton-Suty, C.; Souza, R.; Swift, A. J.; Touyz, R. M.; Ulrich, S.; Wilkins, M. R.; Wort, S. J. 2022 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. European Heart Journal 2022, 43 (38), 3618–3731. [CrossRef]
- Whitlow, P. L.; Feldman, T.; Pedersen, W. R.; Lim, D. S.; Kipperman, R.; Smalling, R.; Bajwa, T.; Herrmann, H. C.; Lasala, J.; Maddux, J. T.; Tuzcu, M.; Kapadia, S.; Trento, A.; Siegel, R. J.; Foster, E.; Glower, D.; Mauri, L.; Kar, S. Acute and 12-Month Results With Catheter-Based Mitral Valve Leaflet Repair. Journal of the American College of Cardiology 2012, 59 (2), 130–139. [CrossRef]
- Stone, G. W.; Lindenfeld, J.; Abraham, W. T.; Kar, S.; Lim, D. S.; Mishell, J. M.; Whisenant, B.; Grayburn, P. A.; Rinaldi, M.; Kapadia, S. R.; Rajagopal, V.; Sarembock, I. J.; Brieke, A.; Marx, S. O.; Cohen, D. J.; Weissman, N. J.; Mack, M. J. Transcatheter Mitral-Valve Repair in Patients with Heart Failure. N Engl J Med 2018, 379 (24), 2307–2318. [CrossRef]
- Stolz, L.; Doldi, P. M.; Sannino, A.; Hausleiter, J.; Grayburn, P. A. The Evolving Concept of Secondary Mitral Regurgitation Phenotypes. JACC: Cardiovascular Imaging 2024, S1936878X24000640. [CrossRef]
- Gucuk Ipek, E.; Singh, S.; Viloria, E.; Feldman, T.; Grayburn, P.; Foster, E.; Qasim, A. Impact of the MitraClip Procedure on Left Atrial Strain and Strain Rate. Circ: Cardiovascular Imaging 2018, 11 (3), e006553. [CrossRef]
- Shafii, A. E.; Gillinov, A. M.; Mihaljevic, T.; Stewart, W.; Batizy, L. H.; Blackstone, E. H. Changes in Left Ventricular Morphology and Function After Mitral Valve Surgery. The American Journal of Cardiology 2012, 110 (3), 403-408.e3. [CrossRef]
- Galli, E.; Hubert, P.; Leurent, G.; Auffret, V.; Panis, V.; L’Official, G.; Donal, E. Acute and Chronic Changes in Myocardial Work Parameters in Patients with Severe Primary Mitral Regurgitation Undergoing Transcatheter Edge-to-Edge Repair. JCDD 2023, 10 (3), 100. [CrossRef]
- Yedidya, I.; Stassen, J.; Butcher, S. C.; Pio, S. M.; Lustosa, R. P.; Van Der Bijl, P.; Vo, N. M.; Namazi, F.; Marsan, N. A.; Delgado, V.; Bax, J. J. Relation of Myocardial Work Indexes and Forward Flow Reserve in Patients With Significant Secondary Mitral Regurgitation Undergoing Transcatheter Mitral Valve Repair. The American Journal of Cardiology 2022, 178, 106–111. [CrossRef]
- Constant Dit Beaufils, A.-L.; Huttin, O.; Jobbe-Duval, A.; Senage, T.; Filippetti, L.; Piriou, N.; Cueff, C.; Venner, C.; Mandry, D.; Sellal, J.-M.; Le Scouarnec, S.; Capoulade, R.; Marrec, M.; Thollet, A.; Beaumont, M.; Hossu, G.; Toquet, C.; Gourraud, J.-B.; Trochu, J.-N.; Warin-Fresse, K.; Marie, P.-Y.; Schott, J.-J.; Roussel, J.-C.; Serfaty, J.-M.; Selton-Suty, C.; Le Tourneau, T. Replacement Myocardial Fibrosis in Patients With Mitral Valve Prolapse: Relation to Mitral Regurgitation, Ventricular Remodeling, and Arrhythmia. Circulation 2021, 143 (18), 1763–1774. [CrossRef]
- Kitkungvan, D.; Yang, E. Y.; El Tallawi, K. C.; Nagueh, S. F.; Nabi, F.; Khan, M. A.; Nguyen, D. T.; Graviss, E. A.; Lawrie, G. M.; Zoghbi, W. A.; Bonow, R. O.; Quinones, M. A.; Shah, D. J. Extracellular Volume in Primary Mitral Regurgitation. JACC: Cardiovascular Imaging 2021, 14 (6), 1146–1160. [CrossRef]
- Stassen, J.; Namazi, F.; Van Der Bijl, P.; Van Wijngaarden, S. E.; Kamperidis, V.; Marsan, N. A.; Delgado, V.; Bax, J. J. Left Atrial Reservoir Function and Outcomes in Secondary Mitral Regurgitation. Journal of the American Society of Echocardiography 2022, 35 (5), 477-485.e3. [CrossRef]
- Toprak, C.; Kahveci, G.; Kilicgedik, A.; Pala, S.; Kirma, C.; Tabakci, M. M.; Inanir, M.; Esen, A. M. Left Atrial Remodeling in Patients Undergoing Percutaneous Mitral Valve Repair with the MitraClip System: An Advanced Echocardiography Study. Echocardiography 2016, 33 (10), 1504–1511. [CrossRef]
- Lavall, D.; Stöbe, S. Myocardial Function in Secondary Mitral Regurgitation: A Challenging Relationship. Circ: Cardiovascular Imaging 2021, 14 (9). [CrossRef]
Figure 1.
Study flowchart. Thirty-two patients were excluded due to an incomplete echocardiographic evaluation or insufficient quality echocardiography imaging.
Figure 1.
Study flowchart. Thirty-two patients were excluded due to an incomplete echocardiographic evaluation or insufficient quality echocardiography imaging.
Figure 2.
Patient follow-up after TEER. The median echocardiographic evaluation follow-up period was six months after TEER. The median clinical follow-up period was 13 months after TEER.
Figure 2.
Patient follow-up after TEER. The median echocardiographic evaluation follow-up period was six months after TEER. The median clinical follow-up period was 13 months after TEER.
Figure 3.
(A) In the first panel, MW indices are evaluated before TEER. (B) In the second panel, MW indices are evaluated six months after TEER. In this case, an impairment of strain and all myocardial indices can be seen (except GWW) after TEER due to an acute reduction in LV preload. GWI is defined as the total work within the area of the LV pressure-strain loop; GCW is the MW during segmental shortening in systole and segmental lengthening during the isovolumic relaxation time; GWW is the work performed during lengthening in systole and shortening during isovolumic relaxation; GWE is the ratio between GCW divided by the sum of GCW and GWW [15,16]. MW, myocardial work; GLS, global longitudinal strain; GWI, global work index; GCW, global constructive work; GWW, global wasted work; GWE, global work efficiency; BP, blood pressure.
Figure 3.
(A) In the first panel, MW indices are evaluated before TEER. (B) In the second panel, MW indices are evaluated six months after TEER. In this case, an impairment of strain and all myocardial indices can be seen (except GWW) after TEER due to an acute reduction in LV preload. GWI is defined as the total work within the area of the LV pressure-strain loop; GCW is the MW during segmental shortening in systole and segmental lengthening during the isovolumic relaxation time; GWW is the work performed during lengthening in systole and shortening during isovolumic relaxation; GWE is the ratio between GCW divided by the sum of GCW and GWW [15,16]. MW, myocardial work; GLS, global longitudinal strain; GWI, global work index; GCW, global constructive work; GWW, global wasted work; GWE, global work efficiency; BP, blood pressure.
Figure 4.
Short-term changes in left and right ventricular performance after TEER (median 6 months, IQR: 3 to 9 months). After TEER, a significant decrease in LVEF was observed (panel A). A significant and early improvement in PASP values and the TAPSE/PASP ratio was noted (panels B and C). An impairment in GWI, GCW, and GWE was detected following the acute reduction in LV preload (panels D, E, and F). LVEF, left ventricular ejection fraction; GWI, global work index; GCW, global constructive work; GWE, global work efficiency; TAPSE, tricuspid annular plane systolic excursion; PASP, pulmonary artery systolic pressure.
Figure 4.
Short-term changes in left and right ventricular performance after TEER (median 6 months, IQR: 3 to 9 months). After TEER, a significant decrease in LVEF was observed (panel A). A significant and early improvement in PASP values and the TAPSE/PASP ratio was noted (panels B and C). An impairment in GWI, GCW, and GWE was detected following the acute reduction in LV preload (panels D, E, and F). LVEF, left ventricular ejection fraction; GWI, global work index; GCW, global constructive work; GWE, global work efficiency; TAPSE, tricuspid annular plane systolic excursion; PASP, pulmonary artery systolic pressure.
Figure 5.
Panel A: Effectiveness of mitral TEER in patients with organic and functional MR (TTE performed a median of 6 months after TEER). Panel B: Heart failure hospitalizations and cardiovascular death (after a median follow-up of 13 months) in patients with organic and functional MR.
Figure 5.
Panel A: Effectiveness of mitral TEER in patients with organic and functional MR (TTE performed a median of 6 months after TEER). Panel B: Heart failure hospitalizations and cardiovascular death (after a median follow-up of 13 months) in patients with organic and functional MR.
Figure 6.
A) Survival analysis according to TAPSE/PASP post-TEER as shown by Kaplan-Meier curves. TAPSE/PASP post-TEER < 0.47 was associated with higher rates of the primary composite endpoint (p-value = 0.039). B) Survival analysis according to LA reservoir post-TEER as shown by Kaplan-Meier curves. LA reservoir < 9.0% was associated with higher rates of the primary composite endpoint (p-value = 0.047).
Figure 6.
A) Survival analysis according to TAPSE/PASP post-TEER as shown by Kaplan-Meier curves. TAPSE/PASP post-TEER < 0.47 was associated with higher rates of the primary composite endpoint (p-value = 0.039). B) Survival analysis according to LA reservoir post-TEER as shown by Kaplan-Meier curves. LA reservoir < 9.0% was associated with higher rates of the primary composite endpoint (p-value = 0.047).
Table 1.
Clinical baseline characteristics of the cohort (one month before TEER). NYHA, New York heart association; ACE-I, angiotensin-converting enzyme inhibitors; ARA, angiotensin receptor antagonist; MRA, mineralocorticoid receptor antagonists; SGLT2, sodium-glucose co-transporter 2.
Table 1.
Clinical baseline characteristics of the cohort (one month before TEER). NYHA, New York heart association; ACE-I, angiotensin-converting enzyme inhibitors; ARA, angiotensin receptor antagonist; MRA, mineralocorticoid receptor antagonists; SGLT2, sodium-glucose co-transporter 2.
| All patients (N=78) | Functional MR (N=29) | Organic MR (N=49) | P-value | |
|---|---|---|---|---|
| Age (year) | 74±9 | 75±9 | 74±9 | 0.898 |
| Sex female | 36 (46.2%) | 16 (55.2%) | 20 (40.8%) | 0.320 |
| Dyslipidemia | 46 (58.9%) | 19 (65.5%) | 33 (67.3%) | 1.000 |
| Diabetes | 34 (43.5%) | 10 (34.4%) | 23 (46.9%) | 0.440 |
| Hypertension | 66 (84.6%) | 25 (86.2%) | 41 (83.6%) | 1.000 |
| Known atrial fibrillation | 49 (62.8%) | 24 (82.7%) | 27 (55.1%) | 0.052 |
| Ischemic heart disease | 36 (46.1%) | 9 (31.0%) | 26 (53.0%) | 0.124 |
| Prior heart failure hospitalization | 54 (69.2%) | 19 (65.5%) | 35 (71.4%) | 0.826 |
| Pacemaker or defibrillation therapy | 6 (7.6%) | 2 (6.8%) | 4 (8.1%) | 1.000 |
| Prior Cardiac Surgery | 18 (26.5%) | 7 (30.4%) | 11 (24.4%) | 0.811 |
| NYHA class: | 0.353 | |||
| NYHA 1 | 1 (1.3%) | 0 (0.0%) | 1 (2.0%) | |
| NYHA 2 | 26 (33.3%) | 13 (44.8%) | 13 (26.6%) | |
| NYHA 3 | 43 (55.1%) | 14 (48.3%) | 29 (59.2%) | |
| NYHA 4 | 8 (10.3%) | 2 (6.90%) | 6 (12.2%) | |
| Chronic renal impairment | 33 (42.3%) | 10 (34.4%) | 22 (44.8%) | 0.644 |
| Chronic obstructive pulmonary disease | 12 (15.3%) | 5 (17.2%) | 7 (14.2%) | 0.738 |
| Furosemide | 71 (91.0%) | 26 (89.6%) | 44 (89.7%) | 1.000 |
| Beta-blockers | 58 (74.3%) | 24 (82.7%) | 35 (71.4%) | 0.583 |
| ACE-I, ARA-2, or sacubitril/valsartan | 38 (48.7%) | 15 (51.7%) | 23 (46.9%) | 0.866 |
| MRA | 33 (42.3%) | 10 (34.4%) | 23 (46.9%) | 0.451 |
| SGLT2-inhibitors | 19 (24.3%) | 11 (37.9%) | 9 (18.3%) | 0.137 |
Table 2.
Echocardiographic baseline characteristics of the cohort (one month before TEER). Significant p-values are in bold. LVEF, left ventricular ejection fraction; LVED, left ventricular end-diastolic volume; LVEDVI, indexed left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; LV GLS, left ventricular global longitudinal strain; GWI, global work index; GCW, global constructive work; GWW, global wasted work; GWE, global work efficiency; MR, mitral regurgitation; EROA, effective regurgitant orifice area; TAPSE, tricuspid annular plane systolic excursion; RV FWS, right ventricular free wall longitudinal strain; TR, tricuspid regurgitation; PASP, pulmonary artery systolic pressure.
Table 2.
Echocardiographic baseline characteristics of the cohort (one month before TEER). Significant p-values are in bold. LVEF, left ventricular ejection fraction; LVED, left ventricular end-diastolic volume; LVEDVI, indexed left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; LV GLS, left ventricular global longitudinal strain; GWI, global work index; GCW, global constructive work; GWW, global wasted work; GWE, global work efficiency; MR, mitral regurgitation; EROA, effective regurgitant orifice area; TAPSE, tricuspid annular plane systolic excursion; RV FWS, right ventricular free wall longitudinal strain; TR, tricuspid regurgitation; PASP, pulmonary artery systolic pressure.
| All patients (N=78) | Functional MR (N=29) | Organic MR (N=49) | P-value | |
|---|---|---|---|---|
| LVEF (%) | 50.0 [36.0;60.0] | 54.0 [40.0;60.0] | 45.0 [35.0;61.0] | 0.427 |
| LVEDV (ml) | 120 [90.8;151] | 102 [84.0;129] | 127 [96.0;153] | 0.048 |
| LVEDVI (ml/m2) | 74.5±29.1 | 60.1 [45.1;72.9] | 74.1 [62.6;84.6] | 0.016 |
| LVESV (ml) | 61.0 [38.0;91.0] | 48.0 [34.2;72.8] | 66.0 [47.0;96.5] | 0.065 |
| LVEDD (mm) | 54.9±8.87 | 54.0±7.46 | 55.4±9.54 | 0.484 |
| LVESD (mm) | 38.0 [31.0;49.0] | 36.0 [32.0;44.0] | 40.5 [31.0;49.8] | 0.361 |
| LV GLS (%) | -13.76±3.88 | -13.68±3.28 | -13.80±4.17 | 0.914 |
| GWI (mmHg%) | 1277±600 | 1281±476 | 1275±654 | 0.966 |
| GCW (mmHg%) | 1628±680 | 1615±489 | 1635±756 | 0.898 |
| GWW (mmHg%) | 149 [96.5;218] | 119 [59.0;184] | 157 [105;225] | 0.094 |
| GWE (%) | 90.0 [84.0;93.5] | 90.0 [87.0;95.0] | 89.0 [81.8;93.0] | 0.124 |
| Left atrial volume index (ml/m2) | 40.6±19.3 | 40.4 [30.8;45.8] | 34.7 [26.4;46.8] | 0.675 |
| Left atrial strain reservoir (%) | 10.0 [7.00;16.0] | 8.00 [7.00;11.0] | 11.0 [7.25;16.8] | 0.118 |
| MR grade: | 0.691 | |||
| MR grade 3 | 20 (25.6%) | 10 (34.5%) | 9 (18.4%) | |
| MR grade 4 | 58 (74.4%) | 19 (65.5%) | 40 (81.6%) | |
| EROA (mm2) | 37.0 [30.0;40.0] | 30.0 [29.2;40.0] | 40.0 [30.0;40.0] | 0.038 |
| Transmitral mean pressure gradient (mmHg) | 2.05 [1.60;2.68] | 1.90 [1.35;2.50] | 2.20 [1.65;2.75] | 0.269 |
| TAPSE (mm) | 17.9±3.79 | 16.9±3.02 | 18.3±4.06 | 0.113 |
| RV FWS (%) | -19.20 [-21.95;-14.20] | -19.10 [-20.25;-14.80] | -19.40 [-25.00;-14.50] | 0.381 |
| Tricuspid regurgitation grade: | 0.083 | |||
| TR ≤ 2 | 51 (65.3%) | 15 (51.7%) | 35 (71.4%) | |
| TR ≥ 3 | 27 (34.7%) | 14 (48.3%) | 14 (28.6%) | |
| PASP (mmHg) | 48.5 [38.8;66.0] | 46.0 [38.5;58.5] | 49.0 [40.0;73.0] | 0.190 |
| TAPSE/PASP | 0.40±0.19 | 0.40±0.15 | 0.40±0.20 | 0.949 |
Table 3.
Left ventricular, left atrial, and right ventricular performance before and after TEER (median follow-up 6 months, IQR: 3 to 9 months). Significant p-values are in bold. LA, left atrial; LVEF, left ventricular ejection fraction; LVED, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; LV GLS, left ventricular global longitudinal strain; GWI, global work index; GCW, global constructive work; GWW, global wasted work; GWE, global work efficiency; LA, left atrial; TAPSE, tricuspid annular plane systolic excursion; RV FWS, right ventricular free wall longitudinal strain; PASP, pulmonary artery systolic pressure. (*) Cut-off according to 2022 ESC Guidelines for the diagnosis and treatment of pulmonary hypertension [19].
Table 3.
Left ventricular, left atrial, and right ventricular performance before and after TEER (median follow-up 6 months, IQR: 3 to 9 months). Significant p-values are in bold. LA, left atrial; LVEF, left ventricular ejection fraction; LVED, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; LV GLS, left ventricular global longitudinal strain; GWI, global work index; GCW, global constructive work; GWW, global wasted work; GWE, global work efficiency; LA, left atrial; TAPSE, tricuspid annular plane systolic excursion; RV FWS, right ventricular free wall longitudinal strain; PASP, pulmonary artery systolic pressure. (*) Cut-off according to 2022 ESC Guidelines for the diagnosis and treatment of pulmonary hypertension [19].
| All patients one month before TEER | All patients six months after TEER | P-Value | |
|---|---|---|---|
| LVEF (%) | 47.37 ± 14.26 | 43.74 ± 15.38 | < 0.001 |
| LVEDV (ml) | 130.59 ± 56.11 | 123.00 ± 53.24 | 0.049 |
| LVESV (ml) | 72.60 ± 47.17 | 71.33 ± 44.69 | 0.584 |
| LVEDD (mm) | 54.81 ± 8.96 | 53.30 ± 9.30 | 0.013 |
| LVESD (mm) | 40.09 ± 11.34 | 39.83 ± 11.57 | 0.742 |
| GLS (%) | -13.28 ± 3.82 | -12.28 ± 3.97 | 0.085 |
| GWI (mmHg%) | 1292.52 ± 608.54 | 1113.89 ± 489.49 | 0.001 |
| GCW (mmHg%) | 1647.15 ± 686.32 | 1438.56 ± 559.95 | 0.009 |
| GWW (mmHg%) | 173.50 ± 126.75 | 202.84 ± 104.63 | 0.062 |
| GWE (mmHg%) | 87.48 ± 8.18 | 85.11 ± 7.73 | 0.007 |
| LA volume (ml) | 70.52 ± 34.10 | 70.04 ± 36.62 | 0.841 |
| LA strain reservoir (%) | 12.03 ± 6.38 | 10.00 ± 4.56 | 0.002 |
| TAPSE (mm) | 17.80 ± 3.90 | 17.97 ± 3.96 | 0.687 |
| RV FWS (%) | -19.36 ± 5.84 | -20.01 ± 5.66 | 0.477 |
| PASP (mmHg) | 53.64 ± 18.64 | 43.86 ± 14.92 | < 0.001 |
| TAPSE/PASP | 0.39 ± 0.19 | 0.45 ± 0.18 | 0.021 |
| TAPSE/PASP < 0.32 (*) | 30 (38.46%) | 13 (16.66%) | 0.006 |
| PASP > 56 mmHg | 33 (42.30%) | 16 (20.51%) | 0.006 |
| PASP > 40 mmHg | 57 (73.07%) | 46 (58.97%) | 0.052 |
Table 4.
Predictors of primary endpoint: heart failure hospitalization and cardiovascular death. Significant p-values are in bold. MR, mitral regurgitation; LVEF, left ventricular ejection fraction; LV GLS, left ventricular global longitudinal strain; GWI, global work index; GCW, global constructive work; GWW, global wasted work; GWE, global work efficiency; LA, left atrial; TAPSE, tricuspid annular plane systolic excursion; PASP, pulmonary artery systolic pressure.
Table 4.
Predictors of primary endpoint: heart failure hospitalization and cardiovascular death. Significant p-values are in bold. MR, mitral regurgitation; LVEF, left ventricular ejection fraction; LV GLS, left ventricular global longitudinal strain; GWI, global work index; GCW, global constructive work; GWW, global wasted work; GWE, global work efficiency; LA, left atrial; TAPSE, tricuspid annular plane systolic excursion; PASP, pulmonary artery systolic pressure.
| Univariable analysis | P-value | Hazard ratio |
|---|---|---|
| Baseline clinical variable | ||
| MR type | 0.280 | 1.67 (0.66-4.22) |
| Age | 0.747 | 1.01 (0.97-1.05) |
| Sex | 0.752 | 1.14 (0.51-2.56) |
| Diabetes | 0.045 | 2.25 (1.02-4.98) |
| Known atrial fibrillation | 0.194 | 1.84 (0.73-4.64) |
| Ischemic heart disease | 0.057 | 2.19 (0.98-4.90) |
| Prior heart failure hospitalization | 0.017 | 3.69 (1.26-10.83) |
| Prior Cardiac Surgery | 0.404 | 0.68 (0.27-1.70) |
| Chronic Kidney disease | 0.187 | 1.70 (0.77-3.73) |
| Chronic obstructive pulmonary disease | 0.523 | 1.42 (0.48-4.17) |
| Baseline TTE variables (one month before TEER) | ||
| LVEF (%) | 0.307 | 0.99 (0.96-1.01) |
| LV GLS (%) | 0.353 | 1.05 (0.94-1.18) |
| GWI (mmHg%) | 0.530 | 1.00 (1.00-1.00) |
| GCW (mmHg%) | 0.474 | 1.00 (1.00-1.00) |
| GWW (mmHg%) | 0.467 | 1.00 (0.99-1.00) |
| GWE (mmHg%) | 0.925 | 1.00 (0.96-1.05) |
| LA volume (ml/m2) | 0.837 | 1.00 (0.98-1.02) |
| LA strain reservoir (%) | 0.122 | 0.94 (0.87-1.02) |
| TAPSE (mm) | 0.545 | 0.97 (0.87-1.08) |
| RV FWS (%) | 0.853 | 0.99 (0.88-1.11) |
| PASP (mmHg) | 0.438 | 1.01 (0.99-1.03) |
| TAPSE/PASP | 0.259 | 0.25 (0.02-2.79) |
| TTE variables six months after TEER (IQR: 3 to 9 months) | ||
| LVEF (%) | 0.377 | 0.99 (0.95-1.02) |
| LV GLS (%) | 0.217 | 1.09 (0.95-1.24) |
| GWI (mmHg%) | 0.230 | 1.00 (1.00-1.00) |
| GCW (mmHg%) | 0.101 | 1.00 (1.00-1.00) |
| GWW (mmHg%) | 0.267 | 1.00 (0.99-1.00) |
| GWE (mmHg%) | 0.932 | 1.00 (0.94-1.06) |
| LA volume (ml) | 0.818 | 1.00 (0.98-1.02) |
| LA strain reservoir (%) | 0.024 | 0.86 (0.76-0.98) |
| TAPSE (mm) | 0.305 | 0.94 (0.84-1.06 |
| RV FWS (%) | 0.552 | 1.06 (0.88-1.26) |
| PASP (mmHg) | 0.247 | 1.02 (0.99-1.06) |
| TAPSE/PASP | 0.038 | 0.02 (0.00-0.80) |
| TAPSE/PASP < 0.47 | 0.039 | 4.76 (1.08-21.02) |
| LA strain reservoir < 9% | 0.047 | 2.77 (1.01-7.59) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
MDPI Initiatives
Important Links
© 2024 MDPI (Basel, Switzerland) unless otherwise stated